Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CDC/NIH VIRAZOLE HANTAVIRUS STUDY HAS ENROLLED 130-140 PATIENTS

Executive Summary

CDC/NIH VIRAZOLE HANTAVIRUS STUDY HAS ENROLLED 130-140 PATIENTS, close to the target enrollment for the study of 150, Centers for Disease Control & Prevention Drug Service Head John Becher said June 30. The open-label trial began enrollment in June 1993, shortly after the outbreak of the virus in May, and is being administered by the National Institutes of Health and CDC in the "Four Corners" area of Colorado, Arizona, New Mexico and Utah. The trial protocol was designed by FDA. CDC is purchasing the study medication, a parenteral formulation of Virazole (ribavirin) from ICN's Viratek subsidiary.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS024732

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel